companydata.dkcompanydata.dk

Ascendis Pharma Endocrinology Division A/S: Financial statements 2016

CVR: 32323537

Source: annual report 2016, Danish Business Authority

01/01/2016 – 31/12/2016

Ascendis Pharma Endocrinology Division A/S (CVR 32323537) has filed annual accounts for 2016. In 2016, the company reported a gross profit of EUR -42,307,040 and a net result of EUR -44,006,494 compared with EUR -29,557,717 the year before. Equity in the 2016 report amounted to EUR -88,262,489.

Gross Profit
EUR -42,307,040
Profit/Loss
EUR -44,006,494
Equity
EUR -88,262,489
Total Assets
EUR 3,665,310

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2016--42.3M EUR-44M EUR-88.3M EUR-
2015--28.8M EUR-29.6M EUR-44.3M EUR-
2014--11.2M EUR-11.5M EUR-14.7M EUR-
2013--46.2M-47.3M-36.9M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Ascendis Pharma Endocrinology Division A/S

Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.

Try the lead list generator

Events in 2016

Ascendis Pharma Endocrinology Division A/S: The 2015 annual report is outMay 9, 2016

Ascendis Pharma Endocrinology Division A/S has published its annual report for 2015. Gross profit came to DKK -28,800,471, and the net result was DKK -29,557,717.

ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S changes name to Ascendis Pharma Endocrinology Division A/SMar 14, 2016

On March 14, 2016, the company changed its name from ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S to Ascendis Pharma Endocrinology Division A/S.

About Ascendis Pharma Endocrinology Division A/S

Ascendis Pharma Endocrinology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S and ACP 30.06.2012 2 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported revenue of EUR 140,817,000 and a net result of EUR -38,806,000 compared with EUR -121,118,000 the year before. Equity in the 2025 report amounted to EUR -935,650,000.

Source: annual report 2025, Danish Business Authority